Sol-Gel (NASDAQ: SLGL) filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 on March 19, 2026, including audited 2025 financial statements.
The Form 20-F is available on the SEC website and the company investor relations site, and a free hard copy is available on request to the CFO.
Sol-Gel is a dermatology company developing SGT-610 (Phase 3, orphan- and breakthrough-designated) for Gorlin syndrome, advancing SGT-210, and commercializing FDA-approved products TWYNEO and EPSOLAY.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SLGL
+8.46%
3 alerts
+8.46%Session close to close
+7.9%Peak Tracked
-8.0%Trough Tracked
$236.79MMarket Cap
0.6xRel. Volume
In the Mar 19 session, SLGL gained 8.46%, reflecting a notable positive market reaction.
Argus tracked a peak move of +7.9% during that session.
Argus tracked a trough of -8.0% from its starting point during tracking.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +8.5% in the session following this news. A strong positive reaction aligns with the...
Analysis
The stock moved +8.5% in the session following this news. A strong positive reaction aligns with the stock’s elevated position above its 200-day MA of 37.33, but investors would need to weigh that enthusiasm against fundamentals disclosed in the 20-F, including recurring net losses of $27.2M, $10.6M, and $6.1M from 2023–2025 and an accumulated deficit of $237M. Past news events have sometimes seen pullbacks, so sustainability would depend on how markets reassess these risks versus the potential of programs like SGT-610.
Key Figures
Share price:$75.34Daily move:-5.53%52-week range:$4.018–$97.97+5 more
8 metrics
Share price$75.34Prior close before 20-F news
Daily move-5.53%24h price change before article
52-week range$4.018–$97.9752-week low and high
Net loss 2025$6.1MFull-year 2025 net loss per Form 20-F summary
Net loss 2024$10.6MFull-year 2024 net loss per Form 20-F summary
Net loss 2023$27.2MFull-year 2023 net loss per Form 20-F summary
Accumulated deficit$237MAs of December 31, 2025 per Form 20-F summary
Twyneo/Epsolay deal$16MUp to upfront and milestone payments from Mayne in April 2025
Q3 2025 results with low revenue, ongoing losses, and pipeline and licensing updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news events, including a trial setback and earnings update, both saw modest share price declines, indicating a tendency for cautious or negative reactions around company updates.
Recent Company History
Over the past several months, Sol-Gel news has centered on its pipeline and financial position. On Nov 20, 2025, Q3 2025 results highlighted low revenue, ongoing losses, and a long cash runway while emphasizing progress on the SGT-610 Phase 3 program. On Dec 17, 2025, a Phase 1b study of SGT-210 in Darier disease failed to show differentiation, leading the company to halt that indication. Both events were followed by share price declines. Today’s Form 20-F filing continues that focus on fundamentals and risk disclosures.
Key Terms
form 20-f, hedgehog inhibitor, egfr inhibitor, phase 3, +4 more
8 terms
form 20-fregulatory
"filed its annual report on Form 20-F for the fiscal year ended"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
hedgehog inhibitormedical
"topical hedgehog inhibitor being developed for the prevention of new basal"
A hedgehog inhibitor is a type of drug that blocks the Hedgehog signaling system, a cellular “on” switch that when stuck can make cells grow uncontrollably in certain cancers. For investors, these drugs matter because successful trial results or regulatory approvals can create new treatment options, drive revenue potential, and change company valuations, while safety problems or failures can sharply reduce expected market value.
egfr inhibitormedical
"SGT-210, an investigational topical EGFR inhibitor for indications with"
An epidermal growth factor receptor (EGFR) inhibitor is a medicine that blocks a specific protein on some cancer cells that acts like a ‘on’ switch for growth; by turning that switch off, the drug can slow or stop tumor growth. Investors care because these drugs are often tied to clear clinical tests, targeted patient groups, patent-protected sales and regulatory decisions, so trial results, safety issues or approvals can sharply change a company’s value.
phase 3medical
"SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
basal cell carcinomamedical
"for the prevention of new basal cell carcinoma (BCC) lesions in patients"
A type of skin cancer that starts in the cells at the bottom layer of the skin and usually grows slowly and stays local rather than spreading to other organs. It matters to investors because its high frequency and generally surgical treatment drive steady demand for diagnostics, procedures, topical or surgical products, and follow‑on therapies, while new drugs, devices or regulatory approvals can shift market value and reimbursement dynamics. Think of it as a common maintenance issue whose repair options and costs influence healthcare spending and related businesses.
bccmedical
"prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin"
bcc is the "blind carbon copy" field in an email that sends a copy to one or more recipients without showing their addresses to others on the message. For investors and corporate communications it matters because it controls who is quietly informed versus publicly notified, which can affect confidentiality, regulatory disclosure duties and the perception of selective information sharing — similar to slipping a copy of a memo to someone without others knowing.
gorlin syndromemedical
"lesions in patients with Gorlin syndrome, with the potential to offer"
A rare inherited genetic condition that increases a person’s lifetime risk of developing multiple skin cancers and other growths, often beginning in childhood or early adulthood. For investors it matters because the small, defined patient group and predictable medical needs make the condition a target for specialized drugs, diagnostics and long‑term care markets; think of it like a known design flaw that creates steady demand for fixes and monitoring.
u.s. securities and exchange commissionregulatory
"filed its annual report on Form 20-F ... with the U.S. Securities and Exchange Commission"
The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.
NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains Sol-Gel’s audited annual financial statements for 2025, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at https://ir.sol-gel.com/financials/sec-filings. The Company will deliver a hard copy of its 2025 annual report on Form 20-F, including its complete audited financial statements, free of charge to its shareholders, upon request to Eyal Ben-Or, Chief Financial Officer, at Eyal.Ben-Or@sol-gel.com.
Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.
To learn more about Sol-Gel, visit www.sol-gel.com
Where can investors access Sol-Gel's Form 20-F for the year ended December 31, 2025 (SLGL)?
You can access the Form 20-F on the SEC website or the company's investor relations site. According to Sol-Gel, the filing includes audited 2025 financial statements and is posted on both the SEC site and the IR website.
How can shareholders request a free hard copy of Sol-Gel's 2025 annual report (SLGL)?
Shareholders can request a free hard copy by contacting the company's CFO via the provided email. According to Sol-Gel, requests should be sent to Eyal.Ben-Or@sol-gel.com and will be fulfilled free of charge.
What is the clinical status of Sol-Gel's lead candidate SGT-610 for Gorlin syndrome (SLGL)?
SGT-610 is in Phase 3 with orphan and breakthrough designations for preventing new BCC lesions in Gorlin syndrome. According to Sol-Gel, SGT-610 is a topical hedgehog inhibitor being developed to potentially improve safety versus oral hedgehog inhibitors.
Does Sol-Gel (SLGL) have any FDA-approved dermatology products?
Yes, Sol-Gel has two FDA-approved products: TWYNEO and EPSOLAY. According to Sol-Gel, these commercial products complement its clinical pipeline and existing dermatology portfolio.
What does filing a Form 20-F mean for Sol-Gel (SLGL) as a Nasdaq-listed company?
Filing Form 20-F provides annual audited financial disclosure required for foreign private issuers listed in the U.S. According to Sol-Gel, the filing supplies audited 2025 financial statements and regulatory transparency for investors.
